Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle.

Xinrong Liu,Kayoko Nakamura,Yi Wang,Dengfeng Cheng,Minmin Liang,Nan Xiao,Ling Chen,Mary Rusckowski,Donald J Hnatowich
DOI: https://doi.org/10.1166/jbn.2010.1111
2010-01-01
Journal of Biomedical Nanotechnology
Abstract:We reported recently that a three-component nanoparticle, consisting of a targeting antibody, a transfecting peptide and an In-111-antiRl alpha MORF antisense oligomer, provided Auger electronmediated, antisense-mediated, cytotoxicity of cells in culture. We have now measured the cytotoxicity of the nanoparticle in culture with the In-111 replaced by I-125, another attractive Auger electron emitter. The nanoparticle consisted of streptavidin linking the I-125 labeled antiRl alpha mRNA antisense MORF oligomer, the tat transfecting peptide and the anti-Her2 Trastuzumab antibody. Cytotoxicity was evaluated by a clonogenic survival assay in BT-474 (Her2+) human breast cancer cells. In a dose escalation study, as measured by the surviving fraction, the cytotoxicity of tumor cells to the I-125-labeled antisense nanoparticle was significantly higher than that for the identical sense control. When compared with our previous study with In-111 as label, a similar level of cytotoxicity was achieved but the observed minimal therapeutic dose for the I-125-labeled nanoparticle in BT-474 cells was lower than that for In-111-labeled nanoparticle in SK-BR-3 cells. Thus, a radiolabeled antisense MORF oligomer delivered into cells by a three-component nanoparticle is an effective vehicle for Auger radiotherapy when radiolabeled with In-111 or I-125.
What problem does this paper attempt to address?